RecruitingNCT06156774

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

130 participants

Start Date

Apr 18, 2024

Study Type

OBSERVATIONAL

Conditions

Non-hodgkin Lymphoma,B Cell

Summary

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (called FIL_SAR-CAR) is looking at whether having sarcopenia (low muscle mass) or being "frail" affects how well patients with a type of blood cancer (B-cell non-Hodgkin Lymphoma) do after receiving a cutting-edge treatment called CAR-T cell therapy. A simplified assessment tool is used to measure frailty before treatment. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with B-cell non-Hodgkin Lymphoma - You are scheduled to receive an approved CAR-T cell therapy - A recent PET/CT scan is available or can be done **You may NOT be eligible if...** - You are not scheduled for CAR-T cell therapy - You are under 18 years old - Required imaging or assessment data cannot be obtained Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERChimeric Antigen Receptor T-cells (CAR-T) therapy

Patients will be treated with CAR-T cell product as per routine clinical practice.

Locations(21)

A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia

Alessandria, Italy

AOU Ospedali Riuniti - Clinica di Ematologia

Ancona, Italy

Azienda Ospedaliera S .Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

Avellino, Italy

IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

Aviano, Italy

ASST Spedali Civili di Brescia - S.C. Ematologia

Brescia, Italy

Ospedale di Castelfranco Veneto - Oncoematologia IOV

Castelfranco Veneto, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

Florence, Italy

ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

Milan, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia

Milan, Italy

Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia

Milan, Italy

A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

Palermo, Italy

Ospedale S. Maria della Misericordia - Ematologia

Perugia, Italy

Ospedale Guglielmo da Saliceto - U.O. Ematologia

Piacenza, Italy

AOU Pisana - U.O. Ematologia

Pisa, Italy

Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

Reggio Emilia, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica S. Cuore - Ematologia

Roma, Italy

Policlinico Umberto I - Università "La Sapienza" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione

Roma, Italy

A.O.U. Citta della Salute e della Scienza di Torino - S.C. Ematologia

Torino, Italy

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - Clinica di Ematologia

Udine, Italy

AOU Integrata di Verona - U.O. Ematologia

Verona, Italy

ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

Vicenza, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06156774

Related Trials

CAR T-cell Therapy in Patients With Renal Dysfunction

NCT059090591 location

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

NCT057413593 locations

Universal CAR-T Cell Therapy for NHL

NCT072481631 location

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

NCT0609016214 locations

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

NCT068388321 location